ArticleClinical ophthalmology (Auckland, N.Z.)2026
Choriocapillaris Flow Deficits Impact Macular Neovascularization Risk in Long-Term Follow-Up for Central Serous Chorioretinopathy.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the influence of choriocapillaris flow deficit on macular neovascularization (MNV) development during extended follow-up for central serous chorioretinopathy (CSC). Design: Retrospective study. Participants: Thirty-six eyes from 36 patients with CSC, each followed for more than 3 years. Methods: All patients underwent comprehensive ophthalmic examinations, including optical coherence tomography (OCT) and OCT angiography (OCTA), at baseline, 3 months from baseline, and the final follow-up. Choriocapillaris flow deficit percentage (CCFD%) was calculated using OCTA images obtained 3 months from baseline. Patients were categorized into two groups based on MNV presence or absence at the final follow-up. Outcome Measures: Association between CCFD% and MNV development. Results: Of the 36 patients, 11 (30.6%) developed MNV during the follow-up period (mean duration: 48.3 ± 14.5 months). The CCFD% at 3 months from baseline was significantly higher in the MNV group than in the non-MNV group (36.6 ± 1.9% vs 35.5 ± 2.3%, p = 0.027). In nine of the 11 eyes (81.8%) with MNV, neovascular lesions spatially corresponded to areas of focal geographic choriocapillaris loss identified at 3 months. Conclusion: CCFD% measured by OCTA may serve as a prognostic biomarker for identifying CSC patients with elevated risk of MNV development. The spatial concordance between regions of choriocapillaris flow deficit and subsequent MNV formation supports the hypothesis that choriocapillaris ischemia substantially contributes to the pathogenesis of MNV in CSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.